Fast Five Quiz: Arthritis

Herbert S. Diamond, MD

Disclosures

July 28, 2020

Updated ACR guidelines on the management of RA are expected to be released in fall 2020. According to current ACR guidelines from 2015, patients with established RA who have moderate or high disease activity and who have never taken a DMARD should receive DMARD monotherapy (methotrexate preferred) over tofacitinib. For patients with established RA who have moderate or high disease activity despite use of a DMARD, TNF inhibitor, or non-TNF biologic therapy, treatment with short-term, low-dose glucocorticoids is recommended. Live attenuated herpes zoster vaccination is not recommended in patients with RA who are taking TNF inhibitor biologics or non-TNF biologics. For patients with symptomatic early RA who have moderate or high disease activity and have never taken a DMARD, the 2015 ACR guidelines recommend DMARD monotherapy over both double and triple therapy.

Read more about the treatment of RA.

This Fast Five Quiz was excerpted and adapted from the Medscape Drugs & Diseases articles Rheumatoid Arthritis and Osteoarthritis.

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....